Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDT Stock Forecast 2026-2027
$3.53
Current Price
$16.67M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CDT Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CDT Price Momentum
-13.5%
1 Week Change
-71.2%
1 Month Change
-99.8%
1 Year Change
-89.0%
Year-to-Date Change
-99.9%
From 52W High of $3,030.00
+35.7%
From 52W Low of $2.60
📊 TOP ANALYST CALLS
Did CDT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Conduit Pharmaceuticals is one of their latest high-conviction picks.
Latest CDT Stock Price Targets & Analyst Predictions
CDT has shown a year-to-date change of -89.0% and a 1-year change of -99.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CDT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDT Analyst Ratings
0
Buy
0
Hold
0
Sell
CDT Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.53
Latest CDT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Conduit Pharmaceuticals Inc. (CDT) Competitors
The following stocks are similar to Conduit Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Conduit Pharmaceuticals Inc. (CDT) Financial Data
Conduit Pharmaceuticals Inc. has a market capitalization of $16.67M with a P/E ratio of 421.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +262.1%.
Valuation Metrics
Market Cap
$16.67M
Enterprise Value
$-1,652,110
P/E Ratio
421.3x
PEG Ratio
2.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1,668.2%
Current Ratio
1.7x
Debt/Equity
43.8x
ROE
+262.1%
ROA
-207.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Conduit Pharmaceuticals Inc. (CDT) Business Model
About Conduit Pharmaceuticals Inc.
What They Do
Develops innovative therapeutic treatments for chronic diseases.
Business Model
Conduit Pharmaceuticals operates by advancing clinical phase drug candidates that target chronic diseases with unmet medical needs. The company generates revenue by developing and potentially commercializing these therapies through collaborations with research institutions and healthcare entities, focusing on high-demand areas like autoimmune disorders and oncology.
Additional Information
Conduit Pharmaceuticals is positioned in the dynamic biotechnology industry, emphasizing scientific research and innovation in drug development. Its commitment to delivering breakthrough therapies aims to address critical health challenges and transform patient care, making it a significant player in the pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6
CEO
Dr. Andrew Regan
Country
United States
IPO Year
2023
Website
www.conduitpharma.comConduit Pharmaceuticals Inc. (CDT) Latest News & Analysis
Latest News
Quick Summary
CDT Equity stock is currently one of the top performers in the market, with gains attributed to unspecified positive developments.
Why It Matters
CDT Equity's strong performance may indicate positive market sentiment, potential growth, or favorable developments, which could attract investor interest and influence stock valuations.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
CDT Equity Inc. noted Sarborg Limited's publication of a research paper on cross-species connectivity in agriculture, which may impact industry insights.
Why It Matters
CDT's acknowledgment of Sarborg Limited's research indicates potential advancements in agricultural tech, which could enhance CDT's position in the market and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
22 days ago
Quick Summary
CDT Equity Inc. has filed two new patent applications to expand its intellectual property on tapinarof, a drug approved for psoriasis and atopic dermatitis.
Why It Matters
The filing of new patent applications by CDT Equity Inc. enhances its intellectual property portfolio, potentially increasing market value and competitive advantage in the drug sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CDT Equity Inc. has mapped its asset portfolio to Sarborg Limited's rare disease database, identifying multiple high-potential opportunities in rare and underserved indications.
Why It Matters
CDT's mapping of its assets to a rare disease database reveals potential growth areas, suggesting increased market value and investment interest in rare disease treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CDT Equity Inc. Announces Reverse Stock Split
23 days ago
Quick Summary
CDT Equity Inc. has approved a 1-for-25 reverse stock split of its common stock, effective as of the announcement date.
Why It Matters
A 1-for-25 reverse stock split typically indicates a company's attempt to boost its stock price and improve its market perception, impacting liquidity and potential investment attractiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CDT Equity Inc. announced that all proposals were approved by stockholders at their Special Meeting on March 17, 2026.
Why It Matters
CDT Equity Inc.'s stockholder approval of all proposals may signal strong investor confidence and potential strategic shifts, impacting future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CDT Stock
What is Conduit Pharmaceuticals Inc.'s (CDT) stock forecast for 2026?
Analyst forecasts for Conduit Pharmaceuticals Inc. (CDT) are not currently available. The stock is trading at $3.53.
Is CDT stock a good investment in 2026?
Analyst ratings for CDT are not currently available. The stock is currently trading at $3.53. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDT stock?
Price predictions from Wall Street analysts for CDT are not currently available. The stock is trading at $3.53.
What is Conduit Pharmaceuticals Inc.'s business model?
Conduit Pharmaceuticals operates by advancing clinical phase drug candidates that target chronic diseases with unmet medical needs. The company generates revenue by developing and potentially commercializing these therapies through collaborations with research institutions and healthcare entities, focusing on high-demand areas like autoimmune disorders and oncology.
What is the highest forecasted price for CDT Conduit Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CDT are not currently available. The stock is trading at $3.53.
What is the lowest forecasted price for CDT Conduit Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CDT are not currently available. The stock is trading at $3.53.
What is the overall CDT consensus from analysts for Conduit Pharmaceuticals Inc.?
Analyst ratings for CDT are not currently available. The stock is trading at $3.53.
How accurate are CDT stock price projections?
Stock price projections, including those for Conduit Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 2:48 AM UTC